Douglas Ingram named president of Allergan

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here each Friday.

Douglas Ingram named president of Allergan

The board of directors at Allergan ($AGN) named Douglas Ingram as the president of the company. For three years, Ingram led the Europe, Africa and Middle East program at Allergan and has been with the company since 1996, when he joined as senior attorney and chief litigation officer. "During his 17-year tenure at Allergan, Doug has consistently demonstrated leadership and high performance across many segments of our business," said Allergan CEO David E. Pyott in a statement. "I am confident that his broad range of commercial and functional experiences will serve him well as he assumes this new and important role." Release

Douglas Ingram will serve as president of the company.

Life Technology
Jonathan Rothberg, who developed solid-state genome sequencing for Life Technologies, has left the company.


Jonathan Rothberg, who developed solid-state genome sequencing for Life Technologies ($LIFE), has left the company. Story

Novavax ($NVAX) has appointed Barclay A. "Buck" Phillips to the position of senior vice president and chief financial officer. Previously, Phillips was senior vice president and chief financial officer of Micromet, which was acquired by Amgen ($AMGN) in 2012. Release

Oxford BioTherapeutics has appointed Bryan Morton as the company's new nonexecutive chairman. Morton was previously CEO of EUSA Pharma, a global specialty oncology company, which was acquired by Jazz Pharmaceuticals ($JAZZ) in 2012. Release

Breaux Castleman has joined Isis Pharmaceuticals' ($ISIS) board of directors. Castleman is president and chief executive officer of Syntiro Healthcare Services. Release

Mylan ($MYL) has appointed Roger Graham as president of Mylan Specialty. Graham joins Mylan from Advandx, where he was the company's chief commercial officer and developed its growth strategy for the U.S. and European markets. Release

Savient Pharmaceuticals ($SVNT) has created a new office of the president, consisting of Richard Crowley, who will serve as co-president and chief operating officer; John P. Hamill, who will serve as co-president and chief financial officer; and Philip K. Yachmetz, who will serve as co-president and chief business officer. Release

NanoViricides has appointed Mukund Kulkarni, professor of finance and chancellor of Penn State University, Harrisburg, as an independent member of the company's board of directors. Release

Abcam picked up Alan Hirzel to be the company's chief marketing officer. Release


AMAG Pharmaceuticals ($AMAG) has appointed Dr. Steven Caffe as chief development and regulatory officer. He joins AMAG from MedImmune, AstraZeneca's ($AZN) global biologics research and development arm, where he most recently served as senior vice president of global regulatory affairs and patient safety. Release

Takeda Pharmaceutical has made a number of senior leadership and organizational changes. Details in the company's release.

Michael S. Holfinger joined Alexza Pharmaceuticals ($ALXA) as vice president of manufacturing and global supply. Release

Drug Delivery

MIT professor and entrepreneur Robert Langer joined CHS Pharma as a member of the company's board of directors and scientific advisory board. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.